CURIUM is a major pharmaceutical company focused on Oncology, Metabolic, Neurology. Key products include DETECTNET.
FDA Novel Drug Designations
(2020)See 1 novel approval →
CURIUM's Key Drugs
CURIUM's core commercial portfolio centers on DETECTNET, BEXLUTRY, spanning Oncology and Metabolic — its most strategically important drugs approved in the last 15 years.
CURIUM's Recent FDA Approvals
CURIUM secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
CURIUM's Therapeutic Areas
CURIUM's approved drugs and pipeline span 4 therapeutic areas, led by Oncology and Metabolic, across 0 biologic and 11 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
CURIUM's Top Competitors
CURIUM's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Eli Lilly, and Roche. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
CURIUM Pipeline Snapshot
CURIUM has 4 active clinical programs from ClinicalTrials.gov — 3 Phase 3, 1 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • DETECTNET leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling